16:42:13 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
Vaccibody är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.

Kalender

2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning VACC 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split VACC 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma
2020-08-27 07:54:52
Oslo, Norway, August 27th, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announces its second quarter results for 2020.

Highlights:

Expansion of Vaccibody’s strategic focus to include Infectious Diseases

Appointment of Gunnstein Norheim, Ph.D., as Director Infectious Diseases leading this new initiative

VB C-02 trial with VB10.16 in combination with Roche’s immune-checkpoint inhibitor atezolizumab in advanced cervical cancer patients approved in all six participating countries, including Norway


Highlights after June 30th, 2020:

Dosing of first patient in VB C-02 Phase II clinical trial with VB10.16 in combination with Roche’s immune-checkpoint inhibitor atezolizumab in advanced cervical cancer

Vaccibody and Nektar Therapeutics dose first patient in Phase I/IIa trial arm evaluating VB10.NEO in combination with bempegaldesleukin (NKTR-214) and immune-checkpoint inhibitor in patients with head and neck cancer

Finalization of patient enrolment in VB N-01 Phase I/IIa clinical trial with VB10.NEO neoantigen cancer vaccine in locally advanced or metastatic cancer patients

Michael Engsig, Chief Executive Officer at Vaccibody, comments:
“This has been a very strong quarter in terms of bringing our projects forward. With the VB C-02 trial in advanced cervical cancer receiving approvals from relevant regulatory authorities in all the participating countries, followed by finalizing enrolment of the VB N-01 trial, this emphasizes our team’s ability to keep our operations running in spite of the challenging Covid-19 situation”

Contact:
CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
E: mengsig@vaccibody.com